284 related articles for article (PubMed ID: 31400507)
21. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
Melillo N; Aarons L; Magni P; Darwich AS
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
[TBL] [Abstract][Full Text] [Related]
22. Qualification of In Vitro Dissolution Absorption System 2 (IDAS2) with Caco-2 and MDCK Cell Monolayers: Dose Sensitivity Study Using BCS Class I and III Drugs.
Higashino H; Develin CF; Higashino C; Lim TC; Miezeiewski BJ; Rawa SL; Strab RJ; Patel R; Bhoopathy S
Biol Pharm Bull; 2024; 47(6):1123-1127. PubMed ID: 38839364
[TBL] [Abstract][Full Text] [Related]
23. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
24. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
[TBL] [Abstract][Full Text] [Related]
25. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
26. [Research on attributes of biopharmaceutics classification system for Chinese materia medica of baicalein in Gegen Qinlian Decoction environment].
Liu Y; Yang L; Zhang X; Cheng YR; Gong YT; Dong L
Zhongguo Zhong Yao Za Zhi; 2019 Sep; 44(17):3653-3661. PubMed ID: 31602937
[TBL] [Abstract][Full Text] [Related]
27. Leveraging BCS in Development: A Case Study.
Hoaglund Hyzer CS; Fadda HM; Rodriguez JO; Aburub A
Mol Pharm; 2015 Oct; 12(10):3685-90. PubMed ID: 26365521
[TBL] [Abstract][Full Text] [Related]
28. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
Rinaki E; Valsami G; Macheras P
Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
[TBL] [Abstract][Full Text] [Related]
29. Investigation into the Emerging Role of the Basic Amino Acid L-Lysine in Enhancing Solubility and Permeability of BCS Class II and BCS Class IV Drugs.
Abdelkader H; Fathalla Z
Pharm Res; 2018 Jun; 35(8):160. PubMed ID: 29916057
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.
Somani AA; Thelen K; Zheng S; Trame MN; Coboeken K; Meyer M; Schnizler K; Ince I; Willmann S; Schmidt S
Br J Clin Pharmacol; 2016 Jan; 81(1):137-47. PubMed ID: 26302359
[TBL] [Abstract][Full Text] [Related]
31. The Evaluation of Valsartan Biopharmaceutics Properties.
de Castro LML; de Souza J; Caldeira TG; de Carvalho Mapa B; Soares AFM; Pegorelli BG; Della Croce CC; Barcellos NMS
Curr Drug Res Rev; 2020; 12(1):52-62. PubMed ID: 31820707
[TBL] [Abstract][Full Text] [Related]
32. In Vitro and In Situ Characterization of Triterpene Glycosides From Cimicifuga racemosa Extract.
Disch L; Forsch K; Siewert B; Drewe J; Fricker G
J Pharm Sci; 2017 Dec; 106(12):3642-3650. PubMed ID: 28827038
[TBL] [Abstract][Full Text] [Related]
33. The biopharmaceutics of successful controlled release drug product: Segmental-dependent permeability of glipizide vs. metoprolol throughout the intestinal tract.
Zur M; Cohen N; Agbaria R; Dahan A
Int J Pharm; 2015 Jul; 489(1-2):304-10. PubMed ID: 25957705
[TBL] [Abstract][Full Text] [Related]
34. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
Newby D; Freitas AA; Ghafourian T
Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
[TBL] [Abstract][Full Text] [Related]
35. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
36. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
37. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
[TBL] [Abstract][Full Text] [Related]
38. [Applicability analysis and evaluation of aglycones in single-pass intestinal perfusion technique based on PBPK model].
Liu Y; Zhang X; Shi XJ; Wen YX; Yang L; Dong L
Zhongguo Zhong Yao Za Zhi; 2019 Sep; 44(17):3645-3652. PubMed ID: 31602936
[TBL] [Abstract][Full Text] [Related]
39. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
40. Biopharmaceutic classification of drugs revisited.
Daousani C; Macheras P
Eur J Pharm Sci; 2016 Dec; 95():82-87. PubMed ID: 27496048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
